M05BA08 • zoledronic acid • Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates
Zoledronic acid is a bisphosphonate used to treat osteoporosis, Paget's disease of the bone, and to prevent skeletal complications in patients with bone metastases. It is also used to treat hypercalcemia associated with cancer.
It works by inhibiting osteoclast-mediated bone resorption, leading to increased bone density and reduced risk of fractures. It is administered intravenously, usually once a year for osteoporosis or more frequently for other indications.
Common side effects include fever, muscle pain, flu-like symptoms, and injection site reactions. In rare cases, it may cause osteonecrosis of the jaw or kidney impairment.
Patients receiving zoledronic acid treatment should be well-hydrated and monitored for kidney function, especially if they have other conditions that may affect the kidneys.
Substance: zoledronic acid
Date of last drug list: 01-01-2019
Commercial code: W08426001
Concentration: 4mg
Pharmaceutical form: powder+solvent for solution for infusion
Quantity: 1
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).